Patient characteristics
| Patients who completed the autoHCT, n = 105 . | N . | % . |
|---|---|---|
| Characteristics at diagnosis | ||
| Female/male | 37/68 | 35/65 |
| Median age, y (range) | 50 (34-70) | |
| Stage 3 | 80 | 76 |
| IgG | 65 | 62 |
| IgA | 18 | 17 |
| BJ | 15 | 14 |
| Nonsecretory | 3 | 2 |
| Creatinine > 2 mg/dL | 12 | 11 |
| β-2-microglobulin > 3.5 μg/mL | 34/78 | 44 |
| Albumin < 3.5 g/dL | 23/71 | 32 |
| ISS 3 | 13/70 | 19 |
| Prior chemotherapy details | ||
| VAD-based induction | 95 | 90 |
| Cycles (median, range [n]) | 4, 2-24 | |
| Patients reinduced after failure of a previous therapy line, n | 21 | 20 |
| Characteristics at autoHCT | ||
| Months between treatment beginning and autoHCT (median, range [n]) | 7, 3-119 | |
| Patients receiving autoHCT within 10 months from treatment beginning, n | 76 | 72 |
| B2M > 3.5 μg/mL at autoHCT | 22/85 | 26 |
| Abnormal cytogenetics by karyotype analysis* | 17/66 | 26 |
| Deletion 13 by 13q14 FISH analysis | 4/18 | 22 |
| Patients who completed the autoHCT, n = 105 . | N . | % . |
|---|---|---|
| Characteristics at diagnosis | ||
| Female/male | 37/68 | 35/65 |
| Median age, y (range) | 50 (34-70) | |
| Stage 3 | 80 | 76 |
| IgG | 65 | 62 |
| IgA | 18 | 17 |
| BJ | 15 | 14 |
| Nonsecretory | 3 | 2 |
| Creatinine > 2 mg/dL | 12 | 11 |
| β-2-microglobulin > 3.5 μg/mL | 34/78 | 44 |
| Albumin < 3.5 g/dL | 23/71 | 32 |
| ISS 3 | 13/70 | 19 |
| Prior chemotherapy details | ||
| VAD-based induction | 95 | 90 |
| Cycles (median, range [n]) | 4, 2-24 | |
| Patients reinduced after failure of a previous therapy line, n | 21 | 20 |
| Characteristics at autoHCT | ||
| Months between treatment beginning and autoHCT (median, range [n]) | 7, 3-119 | |
| Patients receiving autoHCT within 10 months from treatment beginning, n | 76 | 72 |
| B2M > 3.5 μg/mL at autoHCT | 22/85 | 26 |
| Abnormal cytogenetics by karyotype analysis* | 17/66 | 26 |
| Deletion 13 by 13q14 FISH analysis | 4/18 | 22 |
| Patients who completed the alloHCT, n = 102 | ||
| Characteristics at alloHCT | ||
| Median age, y (range) | 52 (35-71) | |
| Age > 60 y | 15 | 15 |
| B2M > 3.5 μg/mL | 16/86 | 19 |
| KPS scale < 90% | 66/99 | 67 |
| HCT-CI score > 2 | 40/97 | 41 |
| AlloHCT conditioning regimen, donors and cell doses | ||
| TBI 2 Gy | 75 | 73 |
| Fludarabine 90 mg/m2 + TBI 2 Gy | 27 | 27 |
| Median donor age, y (range) | 49 (31-73) | |
| Median CD34 infused, ×108/kg (range) | 8.8 (2.0-27.9) | |
| Median CD3 infused, ×106/kg (range) | 3.2 (0.4-11.7) | |
| Postgrafting immunosuppression | ||
| CSP/MMF | 91 | 89 |
| TAC/MMF | 11 | 11 |
| Patients who completed the alloHCT, n = 102 | ||
| Characteristics at alloHCT | ||
| Median age, y (range) | 52 (35-71) | |
| Age > 60 y | 15 | 15 |
| B2M > 3.5 μg/mL | 16/86 | 19 |
| KPS scale < 90% | 66/99 | 67 |
| HCT-CI score > 2 | 40/97 | 41 |
| AlloHCT conditioning regimen, donors and cell doses | ||
| TBI 2 Gy | 75 | 73 |
| Fludarabine 90 mg/m2 + TBI 2 Gy | 27 | 27 |
| Median donor age, y (range) | 49 (31-73) | |
| Median CD34 infused, ×108/kg (range) | 8.8 (2.0-27.9) | |
| Median CD3 infused, ×106/kg (range) | 3.2 (0.4-11.7) | |
| Postgrafting immunosuppression | ||
| CSP/MMF | 91 | 89 |
| TAC/MMF | 11 | 11 |
BJ indicates Bence-Jones; ISS, International Staging System; VAD, vincristine/adriamycin/dexamethasone regimen; and TAC, tacrolimus.
Abnormalities included complex karyotype (n = 13); chromosomal translocations such as t(1;19) (n = 1), t(7;13) (n = 1) and t(11;14)(n = 1) and chromosome 9 inversion (n = 1).